Respuesta humoral inducida por la vacuna BBIBP-CorV/Sinopharm COVID-19 en trabajadores de primera línea

Raúl Montalvo Otivo, Kelina Almora-León, Anibal Diaz-Lazo, José Beraun-Barrantes, M. Tresierra-Ayala, Josdan Montalvo

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

1 Cita (Scopus)

Resumen

With the arrival of the vaccine against COVID-19, the decrease in cases of SARS-CoV-2 infection was evidenced. The objective of the study was to quantify the production of neutralizing antibodies (An) and immunoglobulin G (S-IgG) in frontline workers immunized with two doses of the BBIBP-CorV/Sinopharma vaccine. A cross-sectional analytical observational study was carried out in health personnel immunized with the inactivated vaccine (BBIBP-CorV). Their blood samples were collected three months after the second dose, to measure antibody responses (An, S-IgG). Of a total of 172 people evaluated, 110 (64%) people already had COVID-19 before entering the study, An titers were greater than 10 AU/mL in 60.5% of those vaccinated and 89, 3% showed S-IgG greater than 50 AU/mL. Workers older than 60 years were the group that did not develop enough antibodies. The correlation of An and S-IgG was positive (r=0.84) (p<0.001). The administration of two doses of the inactivated BBIBP-CorV/Sinopharma vaccine caused a notable An and S-IgG response, except in those over 60 years of age.

Título traducido de la contribuciónBBIBP-CorV/Sinopharm COVID-19 vaccine-induced humoral response in frontline workers
Idioma originalEspañol
Páginas (desde-hasta)436-443
Número de páginas8
PublicaciónBoletin de Malariologia y Salud Ambiental
Volumen62
N.º3
DOI
EstadoPublicada - may. 2022

Palabras clave

  • BBIBP-CorV/Sinopharma
  • COVID-19
  • immunoglobulin G
  • neutralizing antibodies
  • SARS-CoV-2
  • vaccines

Huella

Profundice en los temas de investigación de 'Respuesta humoral inducida por la vacuna BBIBP-CorV/Sinopharm COVID-19 en trabajadores de primera línea'. En conjunto forman una huella única.

Citar esto